Delandistrogene Moxeparvovec-Rokl
Last Updated: 04/28/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Treatment advances for Duchenne muscular dystrophy.
Journal: Current opinion in pediatrics
Published: April 01, 2026
Sirolimus for the treatment of steroid-refractory hepatotoxicity following AAV gene therapy in patients with Duchenne muscular dystrophy.
Journal: Journal of neuromuscular diseases
Published: March 19, 2026
Safety and efficacy of commercially administered elevidys (delandistrogene moxeparvovec-rokl).
Journal: Molecular therapy : the journal of the American Society of Gene Therapy
Published: December 02, 2025
ALT/CK Ratio as an Early Marker of Liver Injury After Gene Therapy in Duchenne Muscular Dystrophy.
Journal: Pediatrics
Published: September 04, 2025
FDA Investigating Sarepta's Elevidys® after Second Patient Dies.
Journal: Human gene therapy
Published: August 05, 2025
Engineering Targeted Gene Delivery Systems for Primary Hereditary Skeletal Myopathies: Current Strategies and Future Perspectives.
Journal: Biomedicines
Published: June 10, 2025
Givinostat (Duvyzat) for Duchenne muscular dystrophy.
Journal: The Medical letter on drugs and therapeutics
Published: January 06, 2025
Is Duchenne gene therapy a suitable treatment despite its immunogenic class effect?
Journal: Expert opinion on drug safety
Published: December 25, 2024
The FDA approval of delandistrogene moxeparvovec-rokl for Duchenne muscular dystrophy: a critical examination of the evidence and regulatory process.
Journal: Expert opinion on biological therapy
Published: August 17, 2024
In brief: Expanded indication for Elevidys.
Journal: The Medical letter on drugs and therapeutics
Published: August 13, 2024
Last Updated: 04/28/2026